Dermatology Research and Practice

Dermatology Research and Practice / 2010 / Article
Special Issue

From Melanocyte to Malignant Metastatic Melanoma

View this Special Issue

Research Article | Open Access

Volume 2010 |Article ID 839829 |

John A. H. Lee, "The Determination of Melanoma Stage at Diagnosis", Dermatology Research and Practice, vol. 2010, Article ID 839829, 3 pages, 2010.

The Determination of Melanoma Stage at Diagnosis

Academic Editor: Prashiela Manga
Received15 Dec 2009
Revised11 Mar 2010
Accepted26 May 2010
Published28 Jun 2010


The rising proportion of melanomas diagnosed at an early pathologic stage is commonly ascribed to better public education. However in the US SEER program of cancer registration it has been found that the rates for in situ melanomas are closely related by a log linear relationship to the incidence of invasive melanomas and that this relationship is unrelated to calendar year or gender or patient age. This relationship is sufficiently strong to leave little room for other factors. The relationship may be different in populations with different melanoma rates and responses to them. It is suggested that the results are due to variations within populations of individual response to melanoma cell proliferation.

1. Introduction

Over recent decades in many prosperous white populations the incidence of malignant melanoma of the skin has been rising. Concomitant with this, there has been a shift towards earlier diagnosis, with a consequent improvement in prognosis. This has been ascribed by numerous authors to improved public and professional education [14].

In contrast, it has been shown, in the US population-based cancer registration system, that there is a systematic proportional relationship between incidence rates for in situ melanoma and invasive melanoma in males and females at all ages and over a long time period [5].

This paper explores the relationship between the incidence rate data for in situ and invasive melanoma further. It shows that the proportionate relationship between the in situ and invasive rates is very powerful and leaves room for only a small contribution by any diagnostic or other historical change. An explanation for the link could be found in variations between individuals in resistance to developing melanomas.

2. Data and Methods

The SEER (Statistics Epidemiology and End Results) Program of the U.S. National Cancer Institute (NCI) covers a group of nine geographic areas within the contiguous US that provide population-based cancer registration from 1975 to present. Data from the years 1975 to 2004 for malignant melanoma of the skin were downloaded from the SEER website [6].

This study was restricted to white people. The cases analyzed were restricted to first diagnoses and were all histologically confirmed. Cases were classified at the time of diagnosis as in situ (limited to the epidermis), localized invasive, regional spread, and distant spread. The localized, regional, and distant cases were combined as invasive. The cases unstaged were not analyzed further.

The age range for both males and females was 15–84 in 14 five-year- age groups.

The association between incidence rate of in situ and of invasive melanoma is modeled by Poisson maximum-likelihood regression. Goodness-of-fit of each model was assessed by a pseudo-R-squared measure that compared a model with just the intercept to a model with intercept and coefficient [7].

The data were tabulated using SEER Stat software [8] and analyzed using Stata 9.0. [9].

3. Results

Rates for males and females for single years 1975–2004 and the age range 15–84 are shown for in situ and invasive melanoma for the nine geographic SEER areas combined in Figure 1. The rates are similar in males and females, while, as expected, over time the in situ rates rise much faster than the invasive.

In Table 1 log linear models are shown for males and females relating the in situ and invasive rates for all discrete populations, defined by gender, age from 15 to 84 and period, from 1975–79 to 2000–2004. The confidence limits are very close and the coefficients of variation are close to one.


Male1975–20041.7001.7221.677 14.891 14.806 14.9770.940
Female1975–20042.0972.1382.055 15.760 15.627 15.8930.867

Male1975–792.2752.6071.944 17.358 16.415 18.3000.844
Male1980–841.7771.9471.607 15.708 15.168 16.2480.868
Male1985–891.7021.7961.609 15.101 14.775 15.4270.935
Male1990–941.5941.6591.529 14.537 14.298 14.7770.966
Male1995–991.4721.5161.427 13.937 13.762 14.1120.980
Male2000–041.3781.4121.344 13.419 13.282 13.5570.986

Female1975–791.7662.1861.347 15.750 15.627 15.8930.578
Female1980–841.962.2571.662 15.944 15.116 16.7720.703
Female1985–891.7331.9141.552 14.905 14.375 15.4340.783
Female1990–941.6131.7341.491 14.247 13.882 14.6130.873
Female1995–991.5421.6311.453 13.880 13.592 14.1680.906
Female2000–041.4921.5631.421 13.571 13.332 13.8090.951

The models and rates are shown in Figure 2.

Similar models are also shown in the table for the separate 5-year time periods from 1975–1979 to 2000–2004. The coefficients decline slowly, apparently as the in situ rates approach a maximum (Figure 1). The coefficients of the period specific models for each sex are highly unlikely to be due to chance.

Figure 3 shows the set of 84 observed rates for in situ melanoma and estimated rates derived from the single two-parameter log linear equation and the set of observed invasive rates for males. The picture for females is similar. This is a demonstration (not a test, as there is only one data set) of the power of the relationship and its indifference to time or age.

4. Discussion

The connection between log incidence and log invasive rate for malignant melanoma is a substantial feature of the disease. The real distinction maybe between the tumors that have failed to penetrate into the dermis and those that have. But the precise value of the relationship may be an artifact produced by the original choice invasive rates as the independent variable and in situ rates as the dependent. For instance, a cutting point within the scale of Breslow thickness might be even better.

It is probable that resistance to the multiplication of malignant melanoma cells varies between people, and the systematic relationship between in situ and invasive rates reflects this. In a benign environment, those with the poorest resistance will be the only ones to get a melanoma and will present with the most advanced disease; in a severe environment, stronger resistors will get the disease, but be able to keep it in situ.

The data reported here are combined from nine SEER geographic populations scattered the United States from Detroit to Hawaii. Their separate examination could be helpful. It is possible that in other populations, such as those of Australia and New Zealand with different melanoma rates and different responses, other relationships will be found.


  1. E. Månsson-Brahme, H. Johansson, O. Larsson, L. E. Rutqvist, and U. Ringborg, “Trends in incidence of cutaneous malignant melanoma in a Swedish population 1976–1994,” Acta Oncologica, vol. 41, no. 2, pp. 138–146, 2002. View at: Publisher Site | Google Scholar
  2. M. Coory, P. Baade, J. Aitken, M. Smithers, G. R. C. McLeod, and I. Ring, “Trends for in situ and invasive melanoma in Queensland, Australia, 1982–2002,” Cancer Causes and Control, vol. 17, no. 1, pp. 21–27, 2006. View at: Publisher Site | Google Scholar
  3. A. Downing, J. A. Newton-Bishop, and D. Forman, “Recent trends in cutaneous malignant melanoma in the Yorkshire region of England; incidence, mortality and survival in relation to stage of disease, 1993–2003,” British Journal of Cancer, vol. 95, no. 1, pp. 91–95, 2006. View at: Publisher Site | Google Scholar
  4. B. Peric, J. Zgajnar, N. Besic, and M. Hocevar, “Changing biology of cutaneous melanoma,” Melanoma Research, vol. 18, no. 3, pp. 225–229, 2008. View at: Publisher Site | Google Scholar
  5. J. A. H. Lee, “The systematic relationship between melanomas diagnosed in situ and when invasive,” Melanoma Research, vol. 11, no. 5, pp. 523–529, 2001. View at: Publisher Site | Google Scholar
  6. Surveillance, Epidemiology, and End Results (SEER) Program, “SEER*Stat Database: Incidence—SEER 9 Regs Limited-Use, Nov 2006 Sub (1973–2004), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2007, based on the November 2006 submission,” View at: Google Scholar
  7. J. S. Long and J. Freese, “Scalar measures of fit for regression models,” Stata Technical Bulletin, vol. 10, no. 56, pp. 34–41, 2001. View at: Google Scholar
  8. Surveillance Research Program, National Cancer Institute, “SEER stat software version 6.4.4”. View at: Google Scholar
  9. Stata Corporation, Stata Statistical Software, Release 9, Stata Corporation, College Station, Tex, USA, 2005.

Copyright © 2010 John A. H. Lee. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.